[en] INTRODUCTION: Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE - ClinicalTrials.gov number NCT00408863), a randomized, placebo controlled, double-blind trial which demonstrated that tibolone (Livial), a tissue selective hormone replacement therapy (HRT) increased breast cancer (BC) recurrence HR 1.40 (95% CI 1.14-1.70; p=0.001) entered a subgroup of women into a study of Bone Mineral Density (BMD).
METHODS:
Women with surgically excised primary BC (T1-3, N0-2, M0) within the last 5 years complaining of vasomotor symptoms, were assigned to tibolone 2.5mg daily or placebo treatment for a maximum of 5 years. The BMD sub-study enrolled 763 patients utilizing dual-energy X-ray absorptiometry (DXA) scanning at baseline and at 2 years.
RESULTS:
In the bone sub-study 699 out of 763 women were eligible (345 allocated to tibolone and 354 to placebo) after undergoing DXA scans, 300 (43%) women had normal BMD, 317 (45%) osteopenia and 82 (11.7%) osteoporosis. Low body mass index (<0.001), Asian race (p<0.001) and late age at menarche (p<0.04) predicted for low bone mass at baseline. Tibolone increased BMD by 3.2% at the lumbar spine and 2.9% at the hip compared to placebo (both p<0.001). The majority of fractures (55%) occurred in osteopaenic patients. Women with normal BMD had increased recurrence on tibolone 15.6% (22/141) compared to placebo 6.9% (11/159) p=0.016, whereas no increased BC recurrence was seen in women with low BMD; 7.4% (15/204) on tibolone versus (6.7% (13/195) on placebo.
CONCLUSIONS:
Tibolone is contraindicated after BC treatment as it increases BMD and BC recurrence. Risk of BC recurrence was elevated in BC women with normal BMD (compared to low) who took tibolone.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Bundred, N. J.
Kenemans, P.
Yip, C. H.
Beckmann, M. W.
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Sambrook P, Cooper C. Osteoporosis. Lancet 2006, 17:1369-81.
Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005, 165:552-8. 10.1001/archinte.165.5.552, 15767532.
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, . ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-2. ATAC Trialists' Group.
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, . Intergroup Exemestane Study A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-92. 10.1056/NEJMoa040331, 15014181, Intergroup Exemestane Study.
Coleman RE, Banks L, Girgis SL, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC, . Intergroup Exemestane Study group Skeletal effects of exemestane on bone mineral density, bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES). Lancet Oncol 2007, 8:119-27. 10.1016/S1470-2045(07)70003-7, 17267326, Intergroup Exemestane Study group.
Eastell R, Adams JE, Coleman RE, Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G. Effect of anastrozole on bone mineral density: 5-year results from the anastrazole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008, 26:1051-7. 10.1200/JCO.2007.11.0726, 18309940.
Reid DM, Doughty J, Eastell R, Reid DM, Doughty J, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Guidelines for the management of breast cancer treatment induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 2008, (34):Suppl 1:s3-18.
Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R, . LIFT Trial Investigators The effects of tibolone in older postmenopausal women. N Engl J Med 2008, 359:697-708. 10.1056/NEJMoa0800743, 18703472, LIFT Trial Investigators.
Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW, . LIBERATE Study Group Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind, randomised noninferiority trial. Lancet Oncol 2009, 10:135-46. 10.1016/S1470-2045(08)70341-3, 19167925, LIBERATE Study Group.
Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures; Study of Osteoporotic Fractures Research Group. JAMA 1996, 276:1404-8. 10.1001/jama.1996.03540170048031, 8892715.
Lippman ME, Krueger KA, Eckert S, Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 2001, 19:3111-6.
Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18:1033-46. 10.1007/s00198-007-0343-y, 17323110.
Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008, 112:1001-10. 10.1002/cncr.23259, 18205185.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R, . Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12:631-41. 10.1016/S1470-2045(11)70122-X, 21641868, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011, 22:2546-55. 10.1093/annonc/mdr017, 21415233.
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R, . AZURE Investigators Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365:1396-405. 10.1056/NEJMoa1105195, 21995387, AZURE Investigators.
Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Curr Med Res Opin 2008, 24:807-13. 10.1185/030079908X273282, 18254988.
Walker MD, Babbar R, Opotowsky AR, Rohira A, Nabizadeh F, Badia MD, Chung W, Chiang J, Mediratta A, McMahon D, Liu G, Bilezikian JP. A reference bone mineral density database for Chinese American women. Osteoporos Int 2006, 17:878-87. 10.1007/s00198-005-0059-9, 16538554.
Russell-Aulet M, Wang J, Thornton JC, Colt EW, Pierson RN. Bone mineral density and mass in a cross-sectional study of white and Asian women. J Bone Miner Res 1993, 8:575-82.
Ito M, Lang TF, Jergas M, Ohki M, Takada M, Nakamura T, Hayashi K, Genant HK. Spinal trabecular bone loss and fracture in American and Japanese women. Calcif Tissue Int 1997, 61:123-8. 10.1007/s002239900308, 9236258.
Chen Z, Arendell L, Aickin M, Cauley J, Lewis CE, Chlebowski R, , , , . Women's Health Initiative Program, National Heart, Lung and Blood Institute, US Department of Health and Human Services Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer 2008, 113:907-15. 10.1002/cncr.23674, 2909006, 18666209, Women's Health Initiative Program, National Heart, Lung and Blood Institute, US Department of Health and Human Services.
Kenemans P, Speroff L, . International Tibolone Consensus Group Tibolone: clinical recommendations and practical guidelines: a report of the International Tibolone Consensus Group. Maturitas 2005, 51:21-8. 10.1016/j.maturitas.2005.02.011, 15883105, International Tibolone Consensus Group.
Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008, 358:2355-65. 10.1056/NEJMoa0801197, 18445777.